Symbols / VXRT
VXRT Chart
About
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 177.67M |
| Enterprise Value | 165.04M | Income | -50.70M | Sales | 148.20M |
| Book/sh | 0.12 | Cash/sh | 0.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 105 | IPO | — |
| P/E | — | Forward P/E | -1.37 | PEG | — |
| P/S | 1.20 | P/B | 6.33 | P/C | — |
| EV/EBITDA | -4.12 | EV/Sales | 1.11 | Quick Ratio | 0.68 |
| Current Ratio | 0.69 | Debt/Eq | 70.86 | LT Debt/Eq | — |
| EPS (ttm) | -0.22 | EPS next Y | -0.54 | EPS Growth | — |
| Revenue Growth | 13.68% | Earnings | 2026-03-19 | ROA | -16.25% |
| ROE | -106.52% | ROIC | — | Gross Margin | -20.83% |
| Oper. Margin | -10.79% | Profit Margin | -34.21% | Shs Outstand | 240.06M |
| Shs Float | 237.15M | Short Float | 9.40% | Short Ratio | 2.61 |
| Short Interest | — | 52W High | 0.84 | 52W Low | 0.26 |
| Beta | 1.25 | Avg Volume | 789.38K | Volume | 134.76K |
| Target Price | $3.00 | Recom | None | Prev Close | $0.73 |
| Price | $0.74 | Change | 1.38% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.00
Mean price target
2. Current target
$0.73
Latest analyst target
3. DCF / Fair value
$-0.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.73
Low
$2.00
High
$4.00
Mean
$3.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-03-27 | main | B. Riley Securities | Buy → Buy | $2 |
| 2024-08-15 | init | Oppenheimer | — → Outperform | $4 |
| 2024-01-31 | up | B. Riley Securities | Neutral → Buy | $2 |
| 2023-09-07 | reit | Cantor Fitzgerald | Overweight → Overweight | $4 |
| 2023-08-07 | main | Cantor Fitzgerald | Overweight → Overweight | $4 |
| 2022-12-19 | main | B. Riley Securities | — → Neutral | $2 |
| 2022-09-02 | main | Cantor Fitzgerald | — → Overweight | $8 |
| 2022-05-19 | main | B. Riley Securities | — → Neutral | $6 |
| 2021-11-02 | init | Cantor Fitzgerald | — → Overweight | $15 |
| 2021-06-30 | down | B. Riley Securities | Buy → Neutral | $9 |
| 2021-06-24 | init | Jefferies | — → Buy | $13 |
| 2021-06-11 | init | Piper Sandler | — → Overweight | $18 |
| 2020-08-12 | main | HC Wainwright & Co. | — → Buy | $17 |
| 2020-07-13 | init | B. Riley Securities | — → Buy | $22 |
| 2020-04-30 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2019-06-27 | init | HC Wainwright & Co. | — → Buy | $2 |
- 3 Stocks Under $5 With Strong Analyst Upside Potential - MarketBeat ue, 24 Feb 2026 14
- Lobbying Update: $50,000 of VAXART INC. lobbying was just disclosed - Quiver Quantitative Wed, 21 Jan 2026 08
- Does Vaxart’s (VXRT) Early Norovirus Infant Data Hint At A Broader Oral Vaccine Platform Advantage? - simplywall.st ue, 27 Jan 2026 08
- Vaxart Inc (VXRT) Q3 2025 Earnings Call Highlights: Strategic Partnership and Revenue Surge ... - Yahoo Finance hu, 13 Nov 2025 08
- Vaxart (OTCQX: VXRT) sets Nov. 13 results call and Nov. 18 stockholder chat - Stock Titan Fri, 07 Nov 2025 08
- Vaxart’s Oral Vaccine Bet Hits A Funding Wall - Finimize ue, 13 Jan 2026 08
- $VXRT stock is up 30% today. Here's what we see in our data. - Nasdaq Wed, 11 Jun 2025 07
- Biotech Vaxart Cancels Reverse Split, Doubles Down on Revolutionary Oral Pill Vaccine Platform - Stock Titan Fri, 19 Sep 2025 07
- A Look At Vaxart’s (VXRT) Valuation As New Norovirus Breastfeeding Study Gains Attention - simplywall.st hu, 29 Jan 2026 08
- The 3 Penny Stocks You Swore You’d Never Buy (But You’ll Check Anyway) - MarketBeat Sun, 18 Jan 2026 08
- Vaxart Inc (VXRT) Q2 2025 Earnings Call Highlights: Revenue Surge Amidst Operational Challenges - Yahoo Finance hu, 14 Aug 2025 07
- Vaxart, Inc. Management Asks Stockholders to Approve Reverse Stock Split Proposal by September 4, 2025 - Quiver Quantitative Fri, 08 Aug 2025 07
- Vaxart Moves to OTCQX Best Market While Fighting Nasdaq Delisting - What Investors Should Know - Stock Titan ue, 08 Jul 2025 07
- Vaxart, Inc. (NASDAQ:VXRT) Stock Catapults 34% Though Its Price And Business Still Lag The Industry - simplywall.st Fri, 20 Jun 2025 07
- Major Proxy Firms Back Vaxart's Nasdaq Compliance Strategy Through Reverse Split - Stock Titan hu, 14 Aug 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 151351 | — | — | LO STEVEN | Chief Executive Officer | — | 2025-12-04 00:00:00 | D | nan |
| 1 | 40000 | — | Purchase at price 0.39 - 0.40 per share. | HERON ELAINE J | Director | — | 2025-11-17 00:00:00 | D | 15921.0 |
| 2 | 20000 | — | Purchase at price 0.41 per share. | WATSON WILLIAM MARK | Director | — | 2025-11-17 00:00:00 | D | 8185.0 |
| 3 | 166668 | — | Purchase at price 0.35 - 0.40 per share. | FINNEY KEVIN | Director | — | 2025-08-15 00:00:00 | D | 61934.0 |
| 4 | 10000 | — | Purchase at price 0.40 per share. | WATSON WILLIAM MARK | Director | — | 2025-07-29 00:00:00 | D | 4050.0 |
| 5 | 16000 | — | Stock Award(Grant) at price 0.00 per share. | WHEADON DAVID E. | Director | — | 2025-06-13 00:00:00 | D | — |
| 6 | 6103 | — | Stock Award(Grant) at price 0.00 per share. | FINNEY KEVIN | Director | — | 2025-06-13 00:00:00 | D | — |
| 7 | 16000 | — | Stock Award(Grant) at price 0.00 per share. | HERON ELAINE J | Director | — | 2025-06-13 00:00:00 | D | — |
| 8 | 16000 | — | Stock Award(Grant) at price 0.00 per share. | FINNEY MICHAEL JOSEPH | Director | — | 2025-06-13 00:00:00 | D | — |
| 9 | 16000 | — | Stock Award(Grant) at price 0.00 per share. | WATSON WILLIAM MARK | Director | — | 2025-06-13 00:00:00 | D | — |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -893.34K | -811.62K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -54.87M | -72.13M | -96.33M | -61.67M |
| TotalUnusualItems | 0.00 | -4.25M | -3.01M | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -4.25M | -3.01M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -66.95M | -82.47M | -107.76M | -70.47M |
| ReconciledDepreciation | 8.85M | 8.62M | 5.80M | 4.21M |
| EBITDA | -54.87M | -72.13M | -100.58M | -64.67M |
| EBIT | -63.72M | -80.76M | -106.39M | -68.88M |
| NetInterestIncome | -426.00K | 1.21M | -58.00K | -1.40M |
| InterestExpense | 2.97M | 1.45M | 1.30M | 1.48M |
| InterestIncome | 2.54M | 2.65M | 1.25M | 81.00K |
| NormalizedIncome | -66.95M | -82.47M | -104.40M | -68.28M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -66.95M | -82.47M | -107.76M | -70.47M |
| TotalExpenses | 94.99M | 90.73M | 110.44M | 70.64M |
| TotalOperatingIncomeAsReported | -66.29M | -83.35M | -114.59M | -72.75M |
| DilutedAverageShares | 202.14M | 144.82M | 127.68M | 121.45M |
| BasicAverageShares | 202.14M | 144.82M | 127.68M | 121.45M |
| DilutedEPS | -0.33 | -0.57 | -0.84 | -0.58 |
| BasicEPS | -0.33 | -0.57 | -0.84 | -0.58 |
| DilutedNIAvailtoComStockholders | -66.95M | -82.47M | -107.76M | -70.47M |
| NetIncomeCommonStockholders | -66.95M | -82.47M | -107.76M | -70.47M |
| NetIncome | -66.95M | -82.47M | -107.76M | -70.47M |
| NetIncomeIncludingNoncontrollingInterests | -66.95M | -82.47M | -107.76M | -70.47M |
| NetIncomeContinuousOperations | -66.95M | -82.47M | -107.76M | -70.47M |
| TaxProvision | 260.00K | 261.00K | 67.00K | 107.00K |
| PretaxIncome | -66.69M | -82.20M | -107.69M | -70.36M |
| OtherIncomeExpense | 31.00K | -62.00K | 2.70M | 783.00K |
| OtherNonOperatingIncomeExpenses | 31.00K | -62.00K | 6.95M | 3.79M |
| SpecialIncomeCharges | 0.00 | -4.25M | -3.00M | |
| GainOnSaleOfPPE | 0.00 | |||
| ImpairmentOfCapitalAssets | 0.00 | 4.25M | 3.00M | |
| RestructuringAndMergernAcquisition | 0.00 | |||
| GainOnSaleOfSecurity | -6.00K | -1.00K | ||
| NetNonOperatingInterestIncomeExpense | -426.00K | 1.21M | -58.00K | -1.40M |
| InterestExpenseNonOperating | 2.97M | 1.45M | 1.30M | 1.48M |
| InterestIncomeNonOperating | 2.54M | 2.65M | 1.25M | 81.00K |
| OperatingIncome | -66.29M | -83.35M | -110.33M | -69.75M |
| OperatingExpense | 94.99M | 90.73M | 110.44M | 70.64M |
| ResearchAndDevelopment | 74.21M | 68.14M | 81.05M | 48.75M |
| SellingGeneralAndAdministration | 20.78M | 22.58M | 29.39M | 21.89M |
| GeneralAndAdministrativeExpense | 20.78M | 22.58M | 29.39M | 21.89M |
| OtherGandA | 20.78M | 22.58M | 29.39M | 21.89M |
| TotalRevenue | 28.70M | 7.38M | 107.00K | 892.00K |
| OperatingRevenue | 28.70M | 7.38M | 107.00K | 892.00K |
| Line Item | 2024-12-31 | 2023-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 429.55K | 507.02K | ||
| OrdinarySharesNumber | 227.77M | 153.45M | 134.20M | 125.59M |
| ShareIssued | 228.20M | 153.96M | 134.20M | 125.59M |
| TotalDebt | 17.53M | 20.09M | 21.70M | 13.01M |
| TangibleBookValue | 50.86M | 49.01M | 101.07M | 172.40M |
| InvestedCapital | 58.92M | 57.80M | 110.60M | 187.53M |
| WorkingCapital | -22.62M | 31.81M | 81.53M | 158.38M |
| NetTangibleAssets | 50.86M | 49.01M | 101.07M | 172.40M |
| CapitalLeaseObligations | 17.53M | 20.09M | 21.70M | 13.01M |
| CommonStockEquity | 58.92M | 57.80M | 110.60M | 187.53M |
| TotalCapitalization | 58.92M | 57.80M | 110.60M | 187.53M |
| TotalEquityGrossMinorityInterest | 58.92M | 57.80M | 110.60M | 187.53M |
| StockholdersEquity | 58.92M | 57.80M | 110.60M | 187.53M |
| GainsLossesNotAffectingRetainedEarnings | 4.00K | -1.00K | -299.00K | -74.00K |
| OtherEquityAdjustments | 4.00K | -1.00K | -299.00K | -74.00K |
| TreasuryStock | 350.00K | 366.00K | 0.00 | |
| RetainedEarnings | -476.52M | -409.57M | -327.11M | -219.35M |
| AdditionalPaidInCapital | 535.77M | 467.73M | 437.99M | 406.94M |
| CapitalStock | 23.00K | 15.00K | 13.00K | 13.00K |
| CommonStock | 23.00K | 15.00K | 13.00K | 13.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 107.46M | 34.02M | 43.25M | 33.64M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 16.59M | 20.30M | 25.33M | 22.85M |
| OtherNonCurrentLiabilities | 2.14M | 2.92M | 5.85M | 10.86M |
| LongTermDebtAndCapitalLeaseObligation | 14.45M | 17.39M | 19.48M | 12.00M |
| LongTermCapitalLeaseObligation | 14.45M | 17.39M | 19.48M | 12.00M |
| CurrentLiabilities | 90.88M | 13.72M | 17.92M | 10.78M |
| OtherCurrentLiabilities | 4.06M | 3.80M | 95.00K | 836.00K |
| CurrentDeferredLiabilities | 65.40M | 0.00 | 2.00M | 0.00 |
| CurrentDeferredRevenue | 65.40M | 0.00 | 2.00M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 3.08M | 2.70M | 2.23M | 1.01M |
| CurrentCapitalLeaseObligation | 3.08M | 2.70M | 2.23M | 1.01M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.09M | 4.58M | 3.11M | 2.79M |
| PayablesAndAccruedExpenses | 13.25M | 2.64M | 10.49M | 6.15M |
| CurrentAccruedExpenses | 6.29M | 1.06M | 4.97M | 2.28M |
| Payables | 6.96M | 1.58M | 5.51M | 3.87M |
| AccountsPayable | 6.96M | 1.58M | 5.51M | 3.87M |
| TotalAssets | 166.39M | 91.83M | 153.85M | 221.17M |
| TotalNonCurrentAssets | 98.13M | 46.29M | 54.40M | 52.00M |
| OtherNonCurrentAssets | 839.00K | 926.00K | 3.57M | 890.00K |
| NonCurrentPrepaidAssets | 60.12M | 0.00 | ||
| InvestmentsAndAdvances | 0.00 | 16.21M | ||
| GoodwillAndOtherIntangibleAssets | 8.06M | 8.80M | 9.53M | 15.13M |
| OtherIntangibleAssets | 3.56M | 4.29M | 5.02M | 10.62M |
| Goodwill | 4.51M | 4.51M | 4.51M | 4.51M |
| NetPPE | 29.11M | 36.57M | 41.30M | 19.77M |
| AccumulatedDepreciation | -10.51M | -6.83M | -3.27M | -1.30M |
| GrossPPE | 39.62M | 43.40M | 44.57M | 21.07M |
| Leases | 4.11M | 3.98M | 1.76M | 1.06M |
| ConstructionInProgress | 160.00K | 24.00K | 3.98M | 1.30M |
| OtherProperties | 34.21M | 38.29M | 37.75M | 18.23M |
| MachineryFurnitureEquipment | 1.14M | 1.10M | 1.08M | 481.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 68.26M | 45.54M | 99.45M | 169.17M |
| OtherCurrentAssets | 318.00K | 333.00K | 3.71M | 2.61M |
| RestrictedCash | 2.00M | 0.00 | ||
| PrepaidAssets | 4.25M | 2.48M | 2.61M | |
| Receivables | 11.97M | 3.01M | 20.00K | 71.00K |
| OtherReceivables | 6.21M | |||
| AccountsReceivable | 5.76M | 3.01M | 20.00K | 71.00K |
| CashCashEquivalentsAndShortTermInvestments | 51.72M | 39.71M | 95.72M | 166.49M |
| OtherShortTermInvestments | 26.49M | 4.96M | 49.70M | 22.74M |
| CashAndCashEquivalents | 25.23M | 34.76M | 46.01M | 143.75M |
| CashEquivalents | 16.49M | 31.40M | 28.83M | 70.98M |
| CashFinancial | 8.74M | 3.35M | 15.18M | 72.77M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -45.32M | -72.32M | -104.38M | -64.99M |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 56.29M | 15.03M | 17.24M | 122.21M |
| CapitalExpenditure | -554.00K | -1.87M | -9.60M | -5.16M |
| InterestPaidSupplementalData | 0.00 | |||
| EndCashPosition | 25.23M | 34.76M | 46.01M | 143.75M |
| BeginningCashPosition | 34.76M | 46.01M | 143.75M | 126.87M |
| ChangesInCash | -9.53M | -11.26M | -97.73M | 16.88M |
| FinancingCashFlow | 56.56M | 15.24M | 17.46M | 125.80M |
| CashFlowFromContinuingFinancingActivities | 56.56M | 15.24M | 17.46M | 125.80M |
| NetOtherFinancingCharges | -214.00K | -366.00K | ||
| ProceedsFromStockOptionExercised | 484.00K | 579.00K | 225.00K | 3.59M |
| NetCommonStockIssuance | 56.29M | 15.03M | 17.24M | 122.21M |
| CommonStockIssuance | 56.29M | 15.03M | 17.24M | 122.21M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtPayments | 0.00 | |||
| InvestingCashFlow | -21.32M | 43.95M | -20.41M | -49.10M |
| CashFlowFromContinuingInvestingActivities | -21.32M | 43.95M | -20.41M | -49.10M |
| NetInvestmentPurchaseAndSale | -20.77M | 45.70M | -10.81M | -39.11M |
| SaleOfInvestment | 43.50M | 73.20M | 44.20M | 5.70M |
| PurchaseOfInvestment | -64.27M | -27.50M | -55.01M | -44.81M |
| NetBusinessPurchaseAndSale | 0.00 | -4.83M | ||
| PurchaseOfBusiness | 0.00 | -4.83M | ||
| NetPPEPurchaseAndSale | -554.00K | -1.75M | -9.60M | -5.16M |
| SaleOfPPE | 0.00 | 120.00K | 0.00 | 0.00 |
| PurchaseOfPPE | -554.00K | -1.87M | -9.60M | -5.16M |
| OperatingCashFlow | -44.76M | -70.45M | -94.78M | -59.83M |
| CashFlowFromContinuingOperatingActivities | -44.76M | -70.45M | -94.78M | -59.83M |
| ChangeInWorkingCapital | 3.26M | -10.85M | -4.70M | -2.12M |
| ChangeInOtherWorkingCapital | 65.40M | -2.00M | 2.00M | |
| ChangeInPayablesAndAccruedExpense | 8.61M | -9.42M | -2.97M | -583.00K |
| ChangeInAccruedExpense | 3.33M | -6.98M | -3.32M | -2.21M |
| ChangeInPayable | 5.27M | -2.44M | 357.00K | 1.63M |
| ChangeInAccountPayable | 5.27M | -2.44M | 357.00K | 1.63M |
| ChangeInPrepaidAssets | -61.78M | 3.56M | -3.78M | -1.80M |
| ChangeInReceivables | -8.96M | -2.99M | 51.00K | 263.00K |
| ChangesInAccountReceivables | -2.75M | -2.99M | 51.00K | 263.00K |
| OtherNonCashItems | -668.00K | 710.00K | -5.81M | -3.41M |
| StockBasedCompensation | 11.50M | 14.13M | 13.59M | 8.87M |
| AssetImpairmentCharge | 0.00 | 4.25M | 3.00M | |
| AmortizationOfSecurities | -761.00K | -659.00K | -163.00K | 85.00K |
| DepreciationAmortizationDepletion | 8.85M | 8.62M | 5.80M | 4.21M |
| DepreciationAndAmortization | 8.85M | 8.62M | 5.80M | 4.21M |
| OperatingGainsLosses | 55.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 55.00K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -66.95M | -82.47M | -107.76M | -70.47M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VXRT
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|